Usefulness of a rapid faecal calprotectin test to predict relapse in Crohn’s disease patients on maintenance treatment with adalimumab

References

• Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006;55:426–431.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, González-Lama Y, Maté J. Role of biological markers in inflammatory bowel disease. Gastroenterol Hepatol. 2007;30:117–129.
   PubMedGoogle Scholar
• Poullis A, Foster R, Northfield TC, et al. Review article: faecal markers in the assessment of activity in inflammatory bowel disease. Aliment Pharmacol Ther. 2002;16:675–681.
   PubMed Web of Science ®Google Scholar
• Tibble JA, Sigthorsson G, Foster R, et al. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology. 2002;123:450–460.
   PubMed Web of Science ®Google Scholar
• Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease. Gastroenterology. 2010;138:463–468.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141:1194–1201.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:661–665.
   PubMed Web of Science ®Google Scholar
• Henriksen M, Jahnsen J, Lygren I, et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective longitudinal study. Gut. 2008;57:1518–1523.
   PubMed Web of Science ®Google Scholar
• Johne B, Fagerhol MK, Lyberg T, et al. Functional and clinical aspects of the myelomonocyte protein calprotectin. Mol Pathol. 1997;50:113–123.
   PubMedGoogle Scholar
• Røseth AG, Fagerhol MK, Aadland E, et al. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol. 1992;27:793–798.
   PubMed Web of Science ®Google Scholar
• Konikoff MR, Denson LA. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:524–534.
   PubMed Web of Science ®Google Scholar
• Hoff G, Grotmol T, Thiis-Evensen E, et al. Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT). Gut. 2004;53:1329–1333.
   PubMed Web of Science ®Google Scholar
• Tibble JA, Sigthorsson G, Foster R, et al. High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut. 1999;45:362–366.
   PubMed Web of Science ®Google Scholar
• Ertekin V, Selimoğlu MA, Turgut A, et al. Fecal calprotectin concentration in celiac disease. J Clin Gastroenterol. 2010;44:544–546.
   PubMed Web of Science ®Google Scholar
• Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease. Gut. 2005;54:364–368.
   PubMed Web of Science ®Google Scholar
• D’Incà R, Dal Pont E, Di Leo V, et al. Can calprotectin predict relapse risk in inflammatory bowel disease? Am J Gastroenterol. 2008;103:2007–2014.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Bermejo F, Pérez-Calle JL, et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis. 2009;15:1190–1198.
   PubMed Web of Science ®Google Scholar
• García-Sánchez V, Iglesias-Flores E, González R, et al. Does fecal calprotectin predict relapse in patients with Crohn’s disease and ulcerative colitis? J Crohns Colitis. 2010;4:144–152.
   PubMed Web of Science ®Google Scholar
• Sipponen T, Kolho KL. Faecal calprotectin in children with clinically quiescent inflammatory bowel disease. Scand J Gastroenterol. 2010;45:872–877.
   PubMed Web of Science ®Google Scholar
• Laharie D, Mesli S, El Hajbi F, et al. Prediction of Crohn’s disease relapse with faecal calprotectin in infliximab responders: a prospective study. Aliment Pharmacol Ther. 2011;34:462–469.
   PubMed Web of Science ®Google Scholar
• Wassell J, Wallage M, Brewer E. Evaluation of the Quantum Blue® rapid test for faecal calprotectin. Ann Clin Biochem. 2012;49:55–58.
   PubMed Web of Science ®Google Scholar
• Mao R, Xiao YL, Gao X, et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies. Inflamm Bowel Dis. 2012;18:1894–1899.
   PubMed Web of Science ®Google Scholar
• Hessels J, Douw G, Yildrim DD, et al. Evaluation of Prevent ID and Quantum Blue rapid tests for fecal calprotectin. Clin Chem Lab Med. 2012;50:1079–1082.
   PubMed Web of Science ®Google Scholar
• Tøn H, Brandsnes O, Dale S, et al. Improved assay for fecal calprotectin. Clin Chim Acta. 2000;292:41–54.
   PubMed Web of Science ®Google Scholar
• Tibble J, Teahon K, Thjodleifsson B, et al. A simple method for assessing intestinal inflammation in Crohn’s disease. Gut. 2000;47:506–513.
   PubMed Web of Science ®Google Scholar
• Dolwani S, Metzner M, Wassell JJ, et al. Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology. Aliment Pharmacol Ther. 2004;20:615–621.
   PubMed Web of Science ®Google Scholar
• Molander P, af Björkesten CG, Mustonen H, et al. Fecal calprotectin concentration predicts outcome inflammatory bowel disease after induction therapy with TNFα blocking agents. Inflamm Bowel Dis. 2012;18:2011–2017.
   PubMed Web of Science ®Google Scholar
• Lee KM, Yang SK, Kim HJ, et al. Changes of fecal calprotectin concentrations after adalimumab induction therapy in patients with moderate-to-severe Crohn’s disease. J Crohns Colitis. 2015;9:S362.
   Google Scholar
• Lönnkvist MH, Theodorsson E, Holst M, et al. Blood chemistry markers for evaluation of inflammatory activity in Crohn’s disease during infliximab therapy. Scand J Gastroenterol. 2011;46:420–427.
   PubMed Web of Science ®Google Scholar
• Ferreiro Iglesias R, Barreiro de Acosta M, Otero Santiago M, et al. Fecal calprotectin as predictor of relapse in patients with inflammatory bowel disease under maintenance infliximab therapy. J Clin Gastroenterol. 2015. [Epub ahead of print]. doi: 10.1097/MCG.0000000000000312.
   PubMed Web of Science ®Google Scholar
• Ho GT, Lee HM, Brydon G, et al. Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. Am J Gastroenterol. 2009;104:673–678.
   PubMed Web of Science ®Google Scholar
• Lasson A, Simrén M, Stotzer PO, et al. Fecal calprotectin levels predict the clinical course in patients with new onset of ulcerative colitis. Inflamm Bowel Dis. 2013;19:576–581.
   PubMed Web of Science ®Google Scholar
• De Vos M, Louis EJ, Jahnsen J, et al. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. Inflamm Bowel Dis. 2013;19:2111–2117.
   PubMed Web of Science ®Google Scholar
• Coorevits L, Baert FJ, Vanpoucke HJ. Faecal calprotectin: comparative study of the Quantum Blue rapid test and an established ELISA method. Clin Chem Lab Med. 2013;51:825–831.
   PubMed Web of Science ®Google Scholar
• Sydora MJ, Sydora BC, Fedorak RN. Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome. J Crohns Colitis. 2012;6:207–214.
   PubMed Web of Science ®Google Scholar
• Oyaert M, Trouvé C, Baert F, et al. Comparison of two immunoassays for measurement of faecal calprotectin in detection of inflammatory bowel disease: (pre)-analytical and diagnostic performance characteristics. Clin Chem Lab Med. 2014;52:391–397.
   PubMed Web of Science ®Google Scholar